Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLoans and Notes ReceivablesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Short-Term Debt repayments (2016 - 2023)

Lifecore Biomedical, Inc. \De\ (LFCR) has 12 years of Short-Term Debt repayments data on record, last reported at $12.2 million in Q2 2023.

  • For Q2 2023, Short-Term Debt repayments rose 22.4% year-over-year to $12.2 million; the TTM value through May 2023 reached $54.6 million, up 23.87%, while the annual FY2024 figure was $146.7 million, 168.49% up from the prior year.
  • Short-Term Debt repayments reached $12.2 million in Q2 2023 per LFCR's latest filing, down from $41.6 million in the prior quarter.
  • Across five years, Short-Term Debt repayments topped out at $95.0 million in Q1 2021 and bottomed at $800000.0 in Q4 2022.
  • Average Short-Term Debt repayments over 5 years is $22.1 million, with a median of $17.0 million recorded in 2019.
  • Peak YoY movement for Short-Term Debt repayments: surged 1033.33% in 2019, then tumbled 90.0% in 2022.
  • A 5-year view of Short-Term Debt repayments shows it stood at $37.0 million in 2019, then crashed by 86.49% to $5.0 million in 2020, then skyrocketed by 60.0% to $8.0 million in 2021, then crashed by 90.0% to $800000.0 in 2022, then surged by 1430.0% to $12.2 million in 2023.
  • Per Business Quant database, its latest 3 readings for Short-Term Debt repayments were $12.2 million in Q2 2023, $41.6 million in Q1 2023, and $800000.0 in Q4 2022.